The Copenhagen City Heart Study Experience and its Key Contributions to Chronic Obstructive Pulmonary Disease

Although the principal aim of the Copenhagen City Heart Study (CCHS) was to investigate risk factors for ischaemic heart disease, it already started including spirometry and a questionnaire on respiratory symptoms from its start in 1976. Longitudinal design including five examination rounds and follow-up of hospitalisations, mortality and medically treated exacerbations of chronic obstructive pulmonary disease (COPD) gave a great opportunity to study different aspects of the natural history of COPD. Since 1988, more than 100 papers on different aspects of obstructive lung diseases have been published. Among the most quoted are publications on lung function decline in asthma, trajectories leading to COPD, analyses describing positive association between physical activity and COPD, role of nutritional status for prognosis of COPD, and a nested intervention study showing no effect of an inhaled corticosteroid (ICS) on lung function decline among individuals with mild COPD. The present review describes some of these studies. (BRN Rev.

[1]  B. Nordestgaard,et al.  Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD , 2018, European Respiratory Journal.

[2]  A. Woodcock,et al.  Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability , 2018, European Respiratory Journal.

[3]  B. Nordestgaard,et al.  Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. , 2017, Clinical chemistry.

[4]  J. Vestbo,et al.  Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. , 2016, The Lancet. Respiratory medicine.

[5]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[6]  P. Calverley,et al.  Blood eosinophils as a marker of response to inhaled corticosteroids in COPD , 2016, European Respiratory Journal.

[7]  B. Nordestgaard,et al.  Blood Eosinophils and Exacerbations in COPD: the Copenhagen General Population Study. , 2015 .

[8]  J. Soriano,et al.  Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. , 2015, The New England journal of medicine.

[9]  J. Hallas,et al.  Gastro‐esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease , 2015, Respirology.

[10]  D. Mannino,et al.  Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. , 2024, Chronic obstructive pulmonary diseases.

[11]  J. Hallas,et al.  Statin use and exacerbations in individuals with chronic obstructive pulmonary disease , 2014, Thorax.

[12]  Martijn A Spruit,et al.  Changes in physical activity and all-cause mortality in COPD , 2014, European Respiratory Journal.

[13]  B. Nordestgaard,et al.  Socioeconomic Status and Prognosis of COPD in Denmark , 2014, COPD.

[14]  Meilan K. Han,et al.  Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.

[15]  B. Nordestgaard,et al.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. , 2013, JAMA.

[16]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[17]  Satoshi Konno,et al.  Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[18]  Morten Dahl,et al.  Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. , 2012, American journal of respiratory and critical care medicine.

[19]  B. Nordestgaard,et al.  Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[20]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[21]  Ciro Casanova,et al.  The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. , 2011, American journal of respiratory and critical care medicine.

[22]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[23]  B. Nordestgaard,et al.  C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach , 2010, Thorax.

[24]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[25]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[26]  J. Soriano,et al.  Investigating the natural history of lung function: facts, pitfalls, and opportunities. , 2009, Chest.

[27]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[28]  J. Maurer,et al.  Regular Physical Activity Modifies Smoking-related Lung Function Decline and Reduces Risk of Chronic Obstructive Pulmonary Disease: A Population-based Cohort Study , 2008 .

[29]  J Vestbo,et al.  Developing COPD: a 25 year follow up study of the general population , 2006, Thorax.

[30]  Sun Ha Jee,et al.  Body-mass index and mortality in Korean men and women. , 2006, The New England journal of medicine.

[31]  P. Schnohr,et al.  Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study , 2006, Thorax.

[32]  S. Bojesen,et al.  C-reactive Protein as a Predictor of Prognosis in COPD. , 2006 .

[33]  O. Skjønsberg,et al.  How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? , 2005, Respiratory medicine.

[34]  J. Vestbo,et al.  Social position and mortality from respiratory diseases in males and females , 2003, European Respiratory Journal.

[35]  K Larsson,et al.  Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2003, Respiratory medicine.

[36]  J. Vestbo,et al.  Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study , 2002, European Respiratory Journal.

[37]  J. Vestbo,et al.  Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? , 2002, American journal of respiratory and critical care medicine.

[38]  B. Nordestgaard,et al.  Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[39]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[40]  P. Schnohr,et al.  [The Copenhagen City Heart Study. Joggers live longer]. , 2000, Lakartidningen.

[41]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[42]  tefan,et al.  LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .

[43]  J. Vestbo,et al.  Prognostic value of nutritional status in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[44]  M. Thun,et al.  Body-mass index and mortality in a prospective cohort of U.S. adults. , 1999, The New England journal of medicine.

[45]  J. Vestbo,et al.  Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. , 1999, The European respiratory journal.

[46]  J. Vestbo,et al.  L o n g - t e r m effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised c o n t r o l l e dt r i a l , 1999 .

[47]  J Vestbo,et al.  A 15-year follow-up study of ventilatory function in adults with asthma. , 1998, The New England journal of medicine.

[48]  J. Vestbo,et al.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. , 1996, American journal of respiratory and critical care medicine.

[49]  J. Vestbo,et al.  Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. , 1995, The European respiratory journal.

[50]  J. Vestbo,et al.  Chronic mucus hypersecretion in COPD and death from pulmonary infection. , 1995, The European respiratory journal.

[51]  P. Schnohr,et al.  Phlegm production in plain cigarette smokers who changed to filter cigarettes or quitted smoking , 1990, Journal of internal medicine.

[52]  P. Schnohr,et al.  Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. , 1990, Thorax.

[53]  P. Schnohr,et al.  Determinants of chronic mucus hypersecretion in a general population with special reference to the type of tobacco smoked. , 1989, International journal of epidemiology.

[54]  P. Schnohr,et al.  Effects of smoking and changes in smoking habits on the decline of FEV1. , 1989, The European respiratory journal.

[55]  D. Postma,et al.  Severe chronic airflow obstruction: can corticosteroids slow down progression? , 1985, European journal of respiratory diseases.

[56]  F. Speizer,et al.  The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. , 1983, The American review of respiratory disease.

[57]  J. Tonascia,et al.  Predictive value of respiratory findings. , 1978, Bulletin europeen de physiopathologie respiratoire.

[58]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[59]  M. Lebowitz,et al.  The relationship of acute respiratory illness history to the prevalence and incidence of obstructive lung disorders. , 1977, American journal of epidemiology.

[60]  W. Kannel,et al.  PULMONARY FUNCTION: RELATION TO AGING, CIGARETTE HABIT, AND MORTALITY , 1976 .

[61]  C. Fletcher.  The Natural history of chronic bronchitis and emphysema: An eight-year study of early chronic obstructive lung disease in working men in London , 1976 .

[62]  A. Monto,et al.  The Tecumseh study of respiratory illness. VIII. Acute infection in chronic respiratory disease and comparison groups. , 1975, The American review of respiratory disease.

[63]  Keller Jb,et al.  Seven measures of ventilatory lung function. Population values and a comparison of their ability to discriminate between persons with and without chronic respiratory symptoms and disease, Tecumseh, Michigan. , 1973 .

[64]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.